Durability: Zenkuda has a mean ocular half-life in humans of 20 days, which is 3-fold longer than faricimab 10-90th percentiles 8.3 (10th percentile) 19.8 days (Mean) 5.2 (10 th percentile) t½ <5 days t½ >11 days Faricimab Zenkuda Percent of Patients Each dot represents the ocular half-life from one individual patient. Blue dots are Zenkuda from the Phase 1b study of Zenkuda in patients with wAMD, DME and RVO. Gray dots are faricimab from Genentech, Inc. PK and ER of faricimab, Report # 1105763 0% 81% 10% 10% 0 20 40 60 80 100 Faricimab Zenkuda 31.8 (90th percentile) 11.2 (90 th percentile) 7.5 days (Mean) 10-90th percentiles Human Ocular Half-Life (Days) ~3x longer than faricimab 13